Related Experiment Video
Updated: Jul 11, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation
Minggui Pan1, Monica Santamaria, David B Wollman
1Division of Oncology and Hematology, Department of Pathology, Kaiser Permanente Medical Center, Santa Clara, CA, USA. mingui.pan@kp.org
Background:
A 73-year-old Asian man with a history of lipidemia, hypertension and myocardial infarction presented with dizziness, decreased appetite, weight loss, nonproductive cough and fatigue. His physical performance status was good, and physical examination was unremarkable except for lower-extremity pitting edema.
Investigations:
Physical examination, brain MRI, CT scans of the chest, abdomen and pelvis, bone scan, CT scan-guided biopsy, hematoxylin and eosin staining, EGFR mutational analysis, and chest X-ray.
Diagnosis:
Stage IV non-small-cell lung cancer with brain metastasis.
Management:
Oral erlotinib 150 mg daily for 10 months and ongoing, and whole-brain irradiation.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
